Because fetal hemoglobin contains gammaglobin chains instead of beta chains, it is not affected by the genetic defect that causes sickle cell disease. Increased levels of fetal hemoglobin decrease the tendency toward intracellular polymerization of sickle hemoglobin that characterizes this disease. Hydroxyurea is one of several cytostatic agents that have been shown to increase the production of fetal hemoglobin in some patients with sickle cell disease. We studied the effects of hydroxyurea administration in 10 hospitalized patients with sickle cell disease, each of whom was treated for three months. Seven patients responded with a 2- to 10-fold increase in fetal hemoglobin, from a mean (+/- SD) of 1.6 +/- 1.6 percent of total hemoglobin to 6.8 +/- 4.7 percent; three patients had fetal-hemoglobin levels of 10 to 15 percent of total hemoglobin. Three did not respond to treatment. Four of the patients who responded were retreated with hydroxyurea after one to four months without treatment and were found to have larger increases in fetal-hemoglobin levels. In most patients, levels were still rising at the end of the study, even after 90 days of therapy. Fetal-hemoglobin levels tended to peak at dosages of hydroxyurea that were myelosuppressive. In the patients who responded to treatment, there were significant increases in the percentage of reticulocytes and erythrocytes containing fetal hemoglobin and in the amount of fetal hemoglobin within these cells. The percentage of dense red cells decreased in the patients who responded to treatment. The tendency toward intracellular polymerization at physiologic oxygen saturation was reduced by about 33 percent in the cells containing fetal hemoglobin, whereas there was no change in the other cells. We conclude that hydroxyurea is effective in increasing the production of fetal hemoglobin, which in this study was found to be associated with a small decrease in hemolysis and an increase in hemoglobin levels despite myelosuppression. Controlled, prospective trials are necessary to establish whether these effects will lead to clinical benefit.
Source Information
Laboratory of Chemical Biology, NIDDK, National Institutes of Health, Bethesda, MD 20892.
This article has been cited by other articles:
Bank, A.
(2006). Regulation of human fetal hemoglobin: new players, new complexities. Blood
107: 435-443
[Abstract][Full Text]
Fathallah, H., Atweh, G. F.
(2006). Induction of Fetal Hemoglobin in the Treatment of Sickle Cell Disease. ASH Education Book
2006: 58-62
[Abstract][Full Text]
Tang, D. C., Zhu, J., Liu, W., Chin, K., Sun, J., Chen, L., Hanover, J. A., Rodgers, G. P.
(2005). The hydroxyurea-induced small GTP-binding protein SAR modulates {gamma}-globin gene expression in human erythroid cells. Blood
106: 3256-3263
[Abstract][Full Text]
Weinberg, R. S., Ji, X., Sutton, M., Perrine, S., Galperin, Y., Li, Q., Liebhaber, S. A., Stamatoyannopoulos, G., Atweh, G. F.
(2005). Butyrate increases the efficiency of translation of {gamma}-globin mRNA. Blood
105: 1807-1809
[Abstract][Full Text]
Cao, H., Stamatoyannopoulos, G., Jung, M.
(2004). Induction of human {gamma} globin gene expression by histone deacetylase inhibitors. Blood
103: 701-709
[Abstract][Full Text]
Mak, V, Davies, S C
(2003). The pulmonary physician in critical care * Illustrative case 6: Acute chest syndrome of sickle cell anaemia. Thorax
58: 726-728
[Full Text]
Weiner, D. L., Brugnara, C.
(2003). Hydroxyurea and Sickle Cell Disease: A Chance for Every Patient. JAMA
289: 1692-1694
[Full Text]
Atweh, G. F., DeSimone, J., Saunthararajah, Y., Fathallah, H., Weinberg, R. S., Nagel, R. L., Fabry, M. E., Adams, R. J.
(2003). Hemoglobinopathies. ASH Education Book
2003: 14-39
[Abstract][Full Text]
Setty, B. N. Y., Kulkarni, S., Dampier, C. D., Stuart, M. J.
(2001). Fetal hemoglobin in sickle cell anemia: relationship to erythrocyte adhesion markers and adhesion. Blood
97: 2568-2573
[Abstract][Full Text]
Chaine, B., Neonato, M.-G., Girot, R., Aractingi, S.
(2001). Cutaneous Adverse Reactions to Hydroxyurea in Patients With Sickle Cell Disease. Arch Dermatol
137: 467-470
[Abstract][Full Text]
Skarpidi, E., Vassilopoulos, G., Li, Q., Stamatoyannopoulos, G.
(2000). Novel in vitro assay for the detection of pharmacologic inducers of fetal hemoglobin. Blood
96: 321-326
[Abstract][Full Text]
Hanft, V. N., Fruchtman, S. R., Pickens, C. V., Rosse, W. F., Howard, T. A., Ware, R. E.
(2000). Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood
95: 3589-3593
[Abstract][Full Text]
Smith, R. D., Li, J., Noguchi, C. T., Schechter, A. N.
(2000). Quantitative PCR analysis of HbF inducers in primary human adult erythroid cells. Blood
95: 863-869
[Abstract][Full Text]
Rosse, W. F., Narla, M., Petz, L. D., Steinberg, M. H.
(2000). New Views of Sickle Cell Disease Pathophysiology and Treatment. ASH Education Book
2000: 2-17
[Abstract][Full Text]
Glover, R. E., Ivy, E. D., Orringer, E. P., Maeda, H., Mason, R. P.
(1999). Detection of Nitrosyl Hemoglobin in Venous Blood in the Treatment of Sickle Cell Anemia with Hydroxyurea. Mol. Pharmacol.
55: 1006-1010
[Abstract][Full Text]
Steinberg, M. H.
(1999). Management of Sickle Cell Disease. NEJM
340: 1021-1030
[Full Text]
Maier-Redelsperger, M., de Montalembert, M., Flahault, A., Neonato, M. G., Ducrocq, R., Masson, M.-P., Girot, R., Elion, J., French Study Group on Sickle Cell Disease, t.
(1998). Fetal Hemoglobin and F-Cell Responses to Long-Term Hydroxyurea Treatment in Young Sickle Cell Patients. Blood
91: 4472-4479
[Abstract][Full Text]
Rodriguez, G. I., Kuhn, J. G., Weiss, G. R., Hilsenbeck, S. G., Eckardt, J. R., Thurman, A., Rinaldi, D. A., Hodges, S., Von Hoff, D. D., Rowinsky, E. K.
(1998). A Bioavailability and Pharmacokinetic Study of Oral and Intravenous Hydroxyurea. Blood
91: 1533-1541
[Abstract][Full Text]
Jiang, J., Jordan, S. J., Barr, D. P., Gunther, M. R., Maeda, H., Mason, R. P.
(1997). In Vivo Production of Nitric Oxide in Rats after Administration of Hydroxyurea. Mol. Pharmacol.
52: 1081-1086
[Abstract][Full Text]
Uchida, N., Friera, A. M., He, D., Reitsma, M. J., Tsukamoto, A. S., Weissman, I. L.
(1997). Hydroxyurea Can Be Used to Increase Mouse c-kit+Thy-1.1loLin-/loSca-1+ Hematopoietic Cell Number and Frequency in Cell Cycle In Vivo. Blood
90: 4354-4362
[Abstract][Full Text]
Bunn, H. F.
(1997). Pathogenesis and Treatment of Sickle Cell Disease. NEJM
337: 762-769
[Full Text]
Steinberg, M. H., Lu, Z.-H., Barton, F. B., Terrin, M. L., Charache, S., Dover, G. J., the Multicenter Study of Hydroxyurea,
(1997). Fetal Hemoglobin in Sickle Cell Anemia: Determinants of Response to Hydroxyurea. Blood
89: 1078-1088
[Abstract][Full Text]
Schechter, A. N., Rodgers, G. P., Adams-Graves, P., Heltsley, C., Deitcher, S.
(1996). Hydroxyurea in Sickle Cell Disease. NEJM
334: 333-334
[Full Text]
Sher, G. D., Ginder, G. D., Little, J., Yang, S., Dover, G. J., Olivieri, N. F.
(1995). Extended Therapy with Intravenous Arginine Butyrate in Patients with {beta}-Hemoglobinopathies. NEJM
332: 1606-1610
[Abstract][Full Text]
Griffin, T. C., McIntire, D., Buchanan, G. R.
(1994). High-Dose Intravenous Methylprednisolone Therapy for Pain in Children and Adolescents with Sickle Cell Disease. NEJM
330: 733-737
[Abstract][Full Text]
Weatherall, D.J.
(1993). The Treatment of Thalassemia -- Slow Progress and New Dilemmas. NEJM
329: 877-879
[Full Text]
Blau, C. A.
(1993). Therapy for Globin-Chain Disorders. NEJM
329: 364-364
[Full Text]
Rodgers, G. P., Dover, G. J., Uyesaka, N., Noguchi, C. T., Schechter, A. N., Nienhuis, A. W.
(1993). Augmentation by Erythropoietin of the Fetal-Hemoglobin Response to Hydroxyurea in Sickle Cell Disease. NEJM
328: 73-80
[Abstract][Full Text]
Perrine, S. P., Ginder, G. D., Faller, D. V., Dover, G. H., Ikuta, T., Witkowska, H. E., Cai, S.-p., Vichinsky, E. P., Olivieri, N. F.
(1993). A Short-Term Trial of Butyrate to Stimulate Fetal-Globin-Gene Expression in the {beta}-Globin Disorders. NEJM
328: 81-86
[Abstract][Full Text]
Previous
